Targeting CD44-positive ovarian cancers via engineered paclitaxel prodrug nanoparticles for enhanced chemotherapeutic efficacy

Sun, Xin; Zhao, Rui; Zhao, Eryong; Wang, Qing; Lian, Wenqin; Xiong, Jian

doi:10.1016/j.biopha.2022.113655

Cited by 6 publications

(2 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Conventional paclitaxel drugs are bound by cosolvents as well as liposomal phospholayers, resulting in slow-release kinetics, toxicity, and susceptibility to allergic reactions (114). The albumin-bound PTX (Abraxane) as a surfactant-free formulation of PTX has been authorized to mitigate adverse effects (115). However, the clinical utility of Abraxane remains hindered by its high costs and short in vivo half-life (116).…”

Section: Drug-targeted Deliverymentioning

confidence: 99%

Glycan-based scaffolds and nanoparticles as drug delivery system in cancer therapy

Qin,

Teng,

Dai

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Glycan-based scaffolds are unique in their high specificity, versatility, low immunogenicity, and ability to mimic natural carbohydrates, making them attractive candidates for use in cancer treatment. These scaffolds are made up of glycans, which are biopolymers with well biocompatibility in the human body that can be used for drug delivery. The versatility of glycan-based scaffolds allows for the modulation of drug activity and targeted delivery to specific cells or tissues, which increases the potency of drugs and reduces side effects. Despite their promise, there are still technical challenges in the design and production of glycan-based scaffolds, as well as limitations in their therapeutic efficacy and specificity.

show abstract

Section: Drug-targeted Deliverymentioning

confidence: 99%

Glycan-based scaffolds and nanoparticles as drug delivery system in cancer therapy

Qin,

Teng,

Dai

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…The thorough methodology is described in our previous research. 39 F I G U R E 4 Discrimination and calibration of the signature. (A) The C-index demonstrated that the model outperformed clinical features in predicting the prognosis for OV.…”

Section: Colony-forming and Cell Counting Kit (Cck)-8 Assaysmentioning

confidence: 99%

Ovarian carcinoma immune‐related microRNA affects the heterogeneity of the endocrine microenvironment and anti‐tumor immune pattern

Gao,

Wang,

Xiang

et al. 2023

The Journal of Gene Medicine

Self Cite

View full text Add to dashboard Cite

BackgroundThe eighth‐leading cause of cancer‐related mortality and the seventh‐most prevalent malignancy in women globally is ovarian cancer (OV). However, 5‐year survival expectancy after conventional treatment is not good. Therefore, there is an urgent need for novel signatures to guide the designation of therapeutic schemes for OV patients.MethodsWe used univariate Cox analysis to screen hormone secretion regulation axis‐related microRNAs (miRNAs), least absolute shrinkage and selection operator analysis to select candidate miRNAs and multivariate Cox analysis to build the risk model. To evaluate possible route and functional differences, enrichment analysis using Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) were performed on the differentially expressed genes (DEGs) across various risk groups. We compared Tumor Immune Dysfunction and Exclusion (TIDE) scores across risk categories by analyzing immune cell infiltration, immune checkpoint gene expression, immunological function and TIDE scores. In the end, we determined the half maximal inhibitory concentration (IC50) of chemotherapy and targeted medicines for individual patients. Cell assays were determined to test the migration of the miRNA‐target genes and western blotting was used to test the correlation of the miRNA‐target genes and the pathways.ResultsWe finally identified hormone secretion regulation axis‐related 13 microRNAs to build a risk model. The validation of observed and anticipated values revealed a fair level of agreement. To evaluate the molecular pathways between various groups in accordance with the GO and KEGG analyses, we then discovered 173 DEGs between distinct risk groups. The risk score was shown to be inversely related to the number of immune cells, including myeloid dendritic, granulocytes, M1 and M2 macrophages, B cells, t‐lymphocytes, and CD4+ and CD8+ cells, suggesting that immune cells are more frequent in the low‐risk group. Immune cell infiltration investigation yielded these results. Finally, we recognized 11 chemotherapeutic drugs and 30 novels targeted drugs on the basis of IC50 between the different risk groups. GJB5 was determined to be the mir‐219 target gene and was identified as promoting the cell cycle process. In addition, hormone secretion regulation axis related miRNAs were reported to affects the heterogeneity of endocrine microenvironment and anti‐tumor immune pattern.ConclusionsIn conclusion, a 13‐miRNA prognostic model was constructed to know the immune status, prognosis, immunotherapeutic response and anti‐tumor drug sensitivity for OV, which provides theoretical guidance for the effective and individualized treatment of OV patients.

show abstract

Uncovering the Significance of STEP61 in Alzheimer’s Disease: Structure, Substrates, and Interactome

et al. 2023

View full text Add to dashboard Cite

Targeting CD44-positive ovarian cancers via engineered paclitaxel prodrug nanoparticles for enhanced chemotherapeutic efficacy

Cited by 6 publications

References 34 publications

Glycan-based scaffolds and nanoparticles as drug delivery system in cancer therapy

Glycan-based scaffolds and nanoparticles as drug delivery system in cancer therapy

Ovarian carcinoma immune‐related microRNA affects the heterogeneity of the endocrine microenvironment and anti‐tumor immune pattern

Uncovering the Significance of STEP61 in Alzheimer’s Disease: Structure, Substrates, and Interactome

Contact Info

Product

Resources

About